Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: Results from a multicenter prospective registry

Journal of the American College of Cardiology

Volumn 63, Issue 10, 2014, Pages 982-988

  Lakkireddy, Dhanunjaya ^a   Reddy, Yeruva Madhu ^a   Di Biase, Luigi ^b,c,d   Vallakati, Ajay ^a   Mansour, Moussa C ^e   Santangeli, Pasquale ^b   Gangireddy, Sandeep ^f   Swarup, Vijay ^g   Chalhoub, Fadi ^e   Atkins, Donita ^a   Bommana, Sudharani ^a   Verma, Atul ^h   Sanchez, Javier E ^b   Burkhardt, J David ^b   Barrett, Conor D ^j   Baheiry, Salwa ⁱ   Ruskin, Jeremy ^e   Reddy, Vivek ^g   Natale, Andrea ^b,d  

^a UNIVERSITY OF KANSAS HOSPITAL   (United States)

^b Texas Cardiac Arrhythmia Institute   (United States)

^c UNIVERSITY OF FOGGIA   (Italy)

^d The University of Texas at Austin   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g Arizona Heart Rhythm Center   (United States)

^h Southlake Regional Medical Center   (Canada)

ⁱ CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^j ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

more..

Author keywords

periprocedural anticoagulation; radiofrequency ablation; rivaroxaban; warfarin

Indexed keywords

ANTIVITAMIN K; FRESH FROZEN PLASMA; RIVAROXABAN; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD COMPONENT THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; NORTH AMERICA; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOFREQUENCY ABLATION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; ADVERSE OUTCOME; CLINICAL TRIAL; EMBOLISM; EVENING DOSAGE; HYPERTENSION; KIDNEY FAILURE; LIVER FAILURE; OBSERVATIONAL STUDY;

PERIPROCEDURAL ANTICOAGULATION; RADIOFREQUENCY ABLATION; RIVAROXABAN; WARFARIN;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; REGISTRIES; THIOPHENES; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84896093558     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.11.039     Document Type: Article

References (38)

1. H. Calkins, K.H. Kuck, and R. Cappato et al. Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society Heart Rhythm 4 2012 632 696
2. J.F. Viles-Gonzalez, and D. Mehta Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation Curr Cardiol Rep 1 2011 38 42
3. S.R. Vazquez, S.A. Johnson, and M.T. Rondina Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation Thromb Res 126 2010 e69 e77
4. D.D. Spragg, D. Dalal, and A. Cheema et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors J Cardiovasc Electrophysiol 19 2008 627 631
5. L. Di Biase, J.D. Burkhardt, and P. Mohanty et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio Circulation 121 2010 2550 2556
6. P. Santangeli, L. Di Biase, and R. Horton et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis Circ Arrhythm Electrophysiol 5 2012 302 311
7. A.A. Hussein, D.O. Martin, and W. Saliba et al. Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy Heart Rhythm 6 2009 1425 1429
8. A. Hakalahti, P. Uusimaa, K. Ylitalo, and M.J. Raatikainen Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment Europace 13 2011 640 645
9. O.M. Wazni, S. Beheiry, and T. Fahmy et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period Circulation 116 2007 2531 2534
10. C.M. Rojas-Hernandez, and D.A. Garcia The novel oral anticoagulants Semin Thromb Hemost 39 2013 117 126
11. D. Lakkireddy, Y.M. Reddy, and L. Di Biase et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry J Am Coll Cardiol 59 2012 1168 1174
12. K. Kaseno, S. Naito, and K. Nakamura et al. Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation Circ J 76 2012 2337 2342
13. J.S. Kim, F. She, and K. Jongnarangsin et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation Heart Rhythm 10 2013 483 489
14. M. Bassiouny, W. Saliba, and J. Rickard et al. Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation Circ Arrhythm Electrophysiol 6 2013 460 466
15. H. Yamaji, T. Murakami, K. Hina, and S. Kusachi Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation Clin Drug Invest 33 2013 409 418
16. M.R. Patel, K.W. Mahaffey, and J. Garg et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
17. C. Eitel, J. Koch, and P. Sommer et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation Europace 15 2013 1587 1593
18. J.P. Piccini, S.R. Stevens, and Y. Lokhnygina et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial J Am Coll Cardiol 61 2013 1998 2006
19. US Food and Drug Administration. FDA Access Data. December 2011. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/ 202439s001lbl.pdf. Accessed January 20, 2014.
20. L. Di Biase, J.D. Burkhardt, and P. Mohanty et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation Circulation 122 2010 109 118
21. S. Dixit, and F.E. Marchlinski How to recognize, manage, and prevent complications during atrial fibrillation ablation Heart Rhythm 4 2007 108 115
22. F. Gaita, D. Caponi, and M. Pianelli et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation Circulation 122 2010 1667 1673
23. J. Sra Atrial fibrillation ablation complications J Interv Card Electrophysiol 22 2008 167 172
24. R. Cappato, H. Calkins, and S.A. Chen et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation J Am Coll Cardiol 53 2009 1798 1803
25. A. Takahashi, T. Kuwahara, and Y. Takahashi Complications in the catheter ablation of atrial fibrillation: incidence and management Circ J 73 2009 221 226
26. L. Di Biase, P. Santangeli, and A. Natale How to ablate long-standing persistent atrial fibrillation? Curr Opin Cardiol 28 2013 26 35
27. R. Cappato, H. Calkins, and S.A. Chen et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation Circ Arrhythm Electrophysiol 3 2010 32 38
28. P.D. Bhave, and B.P. Knight Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter Curr Treat Options Cardiovasc Med 15 2013 450 466
29. P. Santangeli, L. Di Biase, J.E. Sanchez, R. Horton, and A. Natale Atrial fibrillation ablation without interruption of anticoagulation Cardiol Res Pract 2011 2011 837841
30. T. Nin, A. Sairaku, and Y. Yoshida et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation Pacing Clin Electrophysiol 36 2013 172 179
31. R.A. Winkle, R.H. Mead, G. Engel, M.H. Kong, and R.A. Patrawala The use of dabigatran immediately after atrial fibrillation ablation J Cardiovasc Electrophysiol 23 2012 264 268
32. D. Lakkireddy, Y.M. Reddy, L. Di Biase, and A. Natale Safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing ablation for atrial fibrillation J Am Coll Cardiol 60 2012 1119 1120
33. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects Eur J Clin Pharmacol 61 2005 873 880
34. D. Kubitza, M. Becka, A. Roth, and W. Mueck Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects Curr Med Res Opin 24 2008 2757 2765
35. W. Mueck, L.C. Borris, and O.E. Dahl et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement Thromb Haemost 100 2008 453 461
36. C.E. Yeo, V. Pillai, and A. Morrison Rivaroxaban and its effect on international normalised ratio-a prospective study of 28 hip and knee arthroplasty patients Am Med J 3 2012 126 129
37. A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (VENTURE-AF). Clinical Trials. 2012. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01729871? term=rivaroxaban+atrial+fibrillation&rank=11. Accessed January 20, 2014.
38. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579